Aleafia Health Inc ALEAF

Alefia has the cure for depression :)

[1hot-techwoman]

Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO(R) Friday, July 24, 2020, 7:14 AM ET Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO(R) -- SPRAVATO(R) (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder -- Aleafia Health medical clinics along with select physicians and nurses now approved to administer and prescribe, following completion of Janssen Journey certification -- Offering expands Aleafia's health and wellness solutions to existing and prospective patients across Canada -- SPRAVATO(R) approved by the U.S. Food and Drug Administration and Health Canada TORONTO, July 24, 2020 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) ("Aleafia Health" or the "Company") today announced that Janssen Pharmaceuticals, Inc. ("Janssen"), has approved its wholly owned subsidiary, Canabo Medical Inc. ("Canabo") as an administrator and prescriber of antidepressant SPRAVATO(R) (esketamine) nasal spray. Three Canabo clinics, including the Company's flagship Toronto location, along with a growing number of clinic network physicians and nurses, are now approved to administer and prescribe SPRAVATO(R) following the Janssen Journey training program's completion. The Company intends to further expand this offering at its nationwide network of clinics and education centres which are staffed by physicians and nurse practitioners and have served over 70,000 unique patients to date. Janssen, a division of Johnson & Johnson (NYSE: JNJ), received U.S. Food and Drug Administration approval for SPRAVATO(R) for use with an oral antidepressant in adults with treatment-resistant depressive disorder (TRD), followed by the drug being made available in Canada on July 22, 2020.